Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syneron Medical has entered into an agreement with Rakuto Bio Technologies or RBT, an Israeli-based start-up, to develop an advanced whole skin complexion whitening treatment.
Subscribe to our email newsletter
RBT has developed a proprietary method for skin whitening through the use of an enzyme derived from a harmless fungus. The RBT product can also be used to treat pigmented lesions. Syneron’s investment will enable RBT to further the development of its innovative product, as well as to pursue other applications for the enzyme to treat other pigmentation disorders. As part of the investment agreement, Syneron will have exclusive, worldwide distribution rights.
Doron Gerstel, CEO of Syneron, said: “Our investment in RBT, like our other investments in complementary technologies, will serve to further diversify both our portfolio of product offerings in the aesthetic sector and our business model.”